MoonLake Immunotherapeutics MLTX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on trailing twelve months.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's free cash flow yield?
- MoonLake Immunotherapeutics (MLTX) reported free cash flow yield of -16.8% in Q1 2026.
- How has MoonLake Immunotherapeutics's free cash flow yield changed year-over-year?
- MoonLake Immunotherapeutics's free cash flow yield decreased by 195.8% year-over-year, from -5.7% to -16.8%.
- What is the long-term trend for MoonLake Immunotherapeutics's free cash flow yield?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's free cash flow yield has grown at a 15.3% compound annual growth rate (CAGR), from -13.7% to -21%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.